Plasmodium drug targets outside the genetic control of the parasite

Current Pharmaceutical Design

Volumn 19, Issue 2, 2013, Pages 282-289

  Sullivan, David J ^a  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Drug; Heme; Host defense peptide; Iron; Malaria

Indexed keywords

8 AMINOQUINOLINE DERIVATIVE; ARTEMISININ DERIVATIVE; CYTOCHROME P450; DEFERIPRONE; DEFEROXAMINE; IRON; METAL CHELATE; PRIMAQUINE; PROTOPORPHYRIN;

ANTIMALARIAL ACTIVITY; ANTIMALARIAL DRUG RESISTANCE; ARTICLE; CONCENTRATION (PARAMETERS); CRYSTALLIZATION; DNA METABOLISM; DRUG CLEARANCE; DRUG TARGETING; ENZYME INHIBITION; ERYTHROCYTE MEMBRANE; GENETIC REGULATION; HOST CELL; HOST RESISTANCE; INNATE IMMUNITY; METABOLITE; NONHUMAN; PLASMODIUM; PRIORITY JOURNAL; SCHIZONT; STRUCTURE ACTIVITY RELATION; TROPHOZOITE;

EID: 84877931102     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161213804070294     Document Type: Article

References (114)

1. Drugs TmcGo. A research agenda for malaria eradication: drugs. PLoS Med 2011; 8(1): e1000402.
2. Gensini GF, Conti AA, Lippi D. The contributions of Paul Ehrlich to infectious disease. J Infect 2007; 54(3): 221-4.
3. Bosch F, Rosich L. The contributions of Paul Ehrlich to pharmacology: a tribute on the occasion of the centenary of his Nobel Prize. Pharmacology 2008; 82(3): 171-9.
4. Adjalley SH, Johnston GL, Li T, et al. Quantitative assessment of Plasmodium falciparum sexual development reveals potent transmission-blocking activity by methylene blue. Proc Natl Acad Sci U S A 2011; 108(47): E1214-23.
5. Coulibaly B, Zoungrana A, Mockenhaupt FP, et al. Strong gametocytocidal effect of methylene blue-based combination therapy against falciparum malaria: a randomised controlled trial. PLoS One 2009; 4(5): e5318.
6. Blank O, Davioud-Charvet E, Elhabiri M. Interactions of the antimalarial drug methylene blue with methemoglobin and heme targets in Plasmodium falciparum: A physico-biochemical study. Antioxid Redox Signal 2012.
7. Schirmer RH, Coulibaly B, Stich A, et al. Methylene blue as an antimalarial agent. Redox Rep 2003; 8(5): 272-5.
8. Atamna H, Krugliak M, Shalmiev G, et al. Mode of antimalarial effect of methylene blue and some of its analogues on Plasmodium falciparum in culture and their inhibition of P. vinckei petteri and P. yoelii nigeriensis in vivo. Biochem Pharmacol 1996; 51(5): 693-700.
9. Bountogo M, Zoungrana A, Coulibaly B, et al. Efficacy of methylene blue monotherapy in semi-immune adults with uncomplicated falciparum malaria: a controlled trial in Burkina Faso. Tropical medicine & international health: TM & IH 2010; 15(6): 713-7.
10. Lee Y, Choi JY, Fu H, et al. Chemistry and biology of macrolide antiparasitic agents. J Med Chem 2011; 54(8): 2792-804.
11. Botte CY, Dubar F, McFadden GI, Marechal E, Biot C. Plasmodium falciparum apicoplast drugs: targets or off-targets? Chem Rev 2012; 112(3): 1269-83.
12. Jelinek T, Ronn AM, Lemnge MM, et al. Polymorphisms in the dihydrofolate reductase (DHFR) and dihydropteroate synthetase (DHPS) genes of Plasmodium falciparum and in vivo resistance to sulphadoxine/pyrimethamine in isolates from Tanzania. Trop Med Int Health 1998; 3(8): 605-9.
13. Curtis J, Duraisingh MT, Warhurst DC. In vivo selection for a specific genotype of dihydropteroate synthetase of Plasmodium falciparum by pyrimethamine-sulfadoxine but not chlorproguanildapsone treatment. J Infect Dis 1998; 177(5): 1429-33.
14. Wang P, Brobey RK, Horii T, Sims PF, Hyde JE. Utilization of exogenous folate in the human malaria parasite Plasmodium falciparum and its critical role in antifolate drug synergy. Mol Microbiol 1999; 32(6): 1254-62.
15. Mather MW, Darrouzet E, Valkova-Valchanova M, et al. Uncovering the molecular mode of action of the antimalarial drug atovaquone using a bacterial system. J Biol Chem 2005; 280(29): 27458-65.
16. Musk P. Magic shotgun methods for developing drugs for CNS disorders. Discov Med 2004; 4(23): 299-302.
17. Roth BL, Sheffler DJ, Kroeze WK. Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia. Nat Rev Drug Discov 2004; 3(4): 353-9.
18. Vale N, Moreira R, Gomes P. Primaquine revisited six decades after its discovery. Eur J Med Chem 2009; 44(3): 937-53.
19. Bhisutthibhan J, Pan XQ, Hossler PA, et al. The Plasmodium falciparum translationally controlled tumor protein homolog and its reaction with the antimalarial drug artemisinin. J Biol Chem 1998; 273(26): 16192-8.
20. Hong YL, Yang YZ, Meshnick SR. The interaction of artemisinin with malarial hemozoin. Mol Biochem Parasitol 1994; 63(1): 121-8.
21. Meshnick SR. Artemisinin: mechanisms of action, resistance and toxicity. Int J Parasitol 2002; 32(13): 1655-60.
22. Meshnick SR, Taylor TE, Kamchonwongpaisan S. Artemisinin and the antimalarial endoperoxides: from herbal remedy to targeted chemotherapy. Microbiol Rev 1996; 60(2): 301-15.
23. Eckstein-Ludwig U, Webb RJ, Van Goethem ID, et al. Artemisinins target the SERCA of Plasmodium falciparum. Nature 2003; 424(6951): 957-61.
24. Pisciotta JM, Sullivan D. Hemozoin: oil versus water. Parasitol Int 2008; 57(2): 89-96.
25. Sullivan DJ, Jr., Gluzman IY, Russell DG, Goldberg DE. On the molecular mechanism of chloroquine's antimalarial action. Proc Natl Acad Sci U S A 1996; 93(21): 11865-70.
26. Weissbuch I, Leiserowitz L. Interplay between malaria, crystalline hemozoin formation, and antimalarial drug action and design. Chem Rev 2008; 108(11): 4899-914.
27. Bruce-Chwatt LJ. Three hundred and fifty years of the Peruvian fever bark. Br Med J (Clin Res Ed) 1988; 296(6635): 1486-7.
28. Delepine M. Joseph Pelletier and Joseph Caventou. J Chem Educ 1951; 28(9): 454-61.
29. Taylor WR, White NJ. Antimalarial drug toxicity: a review. Drug Saf 2004; 27(1): 25-61.
30. Touze JE, Heno P, Fourcade L, et al. The effects of antimalarial drugs on ventricular repolarization. Am J Trop Med Hyg 2002; 67(1): 54-60.
31. Bacon P, Spalton DJ, Smith SE. Blindness from quinine toxicity. Br J Ophthalmol 1988; 72(3): 219-24.
32. Vipan WH. Quinine as a cause of purpura. Lancet 1865; 86(2184): 37.
33. Sullivan DJ, Jr., Matile H, Ridley RG, Goldberg DE. A common mechanism for blockade of heme polymerization by antimalarial quinolines. J Biol Chem 1998; 273(47): 31103-7.
34. Peters W. Plasmodium: resistance to antimalarial drugs. Ann Parasitol Hum Comp 1990; 65 Suppl 1103-6.
35. van den Broek IV, van der Wardt S, Talukder L, et al. Drug resistance in Plasmodium falciparum from the Chittagong Hill Tracts, Bangladesh. Trop Med Int Health 2004; 9(6): 680-7.
36. Na-Bangchang K, Congpuong K. Current malaria status and distribution of drug resistance in East and Southeast Asia with special focus to Thailand. Tohoku J Exp Med 2007; 211(2): 99-113.
37. Wise R. A review of the mechanisms of action and resistance of antimicrobial agents. Can Respir J 1999; 6 Suppl A20A-2A.
38. Savas B, Cole SP, Akoglu TF, Pross HF. P-glycoprotein-mediated multidrug resistance and cytotoxic effector cells. Nat Immun 1992; 11(4): 177-92.
39. Bhullar K, Waglechner N, Pawlowski A, et al. Antibiotic resistance is prevalent in an isolated cave microbiome. PLoS One 2012; 7(4): e34953.
40. Drewniak L, Styczek A, Majder-Lopatka M, Sklodowska A. Bacteria, hypertolerant to arsenic in the rocks of an ancient gold mine, and their potential role in dissemination of arsenic pollution. Environ Pollut 2008; 156(3): 1069-74.
41. Aurrecoechea C, Brestelli J, Brunk BP, et al. PlasmoDB: a functional genomic database for malaria parasites. Nucleic Acids Res 2009; 37(Database issue): D539-43.
42. Berger BJ, Martiney J, Slater AF, Fairlamb AH, Cerami A. Chloroquine resistance is not associated with drug metabolism in Plasmodium falciparum. J Parasitol 1995; 81(6): 1004-8.
43. Robert A, Dechy-Cabaret O, Cazelles J, Meunier B. From mechanistic studies on artemisinin derivatives to new modular antimalarial drugs. Acc Chem Res 2002; 35(3): 167-74.
44. Posner GH, O'Neill PM. Knowledge of the proposed chemical mechanism of action and cytochrome p450 metabolism of antimalarial trioxanes like artemisinin allows rational design of new antimalarial peroxides. Acc Chem Res 2004; 37(6): 397-404.
45. Muller IB, Hyde JE. Antimalarial drugs: modes of action and mechanisms of parasite resistance. Future Microbiol 2010; 5(12): 1857-73.
46. Wellems TE, Plowe CV. Chloroquine-resistant malaria. J Infect Dis 2001; 184(6): 770-6.
47. Roepe PD. PfCRT-Mediated Drug Transport in Malarial Parasites. Biochemistry 2010.
48. Valderramos SG, Fidock DA. Transporters involved in resistance to antimalarial drugs. Trends Pharmacol Sci 2006; 27(11): 594-601.
49. Woodrow CJ, Krishna S. Antimalarial drugs: recent advances in molecular determinants of resistance and their clinical significance. Cell Mol Life Sci 2006; 63(14): 1586-96.
50. Chandra R, Kumar S, Puri SK. Plasmodium vinckei: infectivity of arteether-sensitive and arteether-resistant parasites in different strains of mice. Parasitol Res 2011; 109(4): 1143-9.
51. Wood PA, Eaton JW. Hemoglobin catabolism and host-parasite heme balance in chloroquine-sensitive and chloroquine-resistant Plasmodium berghei infections. Am J Trop Med Hyg 1993; 48(4): 465-72.
52. Biarnais T, Landau I, Richard-Lenoble D. Changes in schizogony and drug response in two lines of rodent Plasmodium, P. berghei NK 65 and P. berghei ANKA. Parasite 2002; 9(1): 51-7.
53. Paget-McNicol S, Saul A. Mutation rates in the dihydrofolate reductase gene of Plasmodium falciparum. Parasitology 2001; 122(Pt 5): 497-505.
54. Berry A, Senescau A, Lelievre J, et al. Prevalence of Plasmodium falciparum cytochrome b gene mutations in isolates imported from Africa, and implications for atovaquone resistance. Trans R Soc Trop Med Hyg 2006; 100(10): 986-8.
55. Rathod PK, McErlean T, Lee PC. Variations in frequencies of drug resistance in Plasmodium falciparum. Proc Natl Acad Sci U S A 1997; 94(17): 9389-93.
56. White NJ. Antimalarial drug resistance. J Clin Invest 2004; 113(8): 1084-92.
57. White NJ. Delaying antimalarial drug resistance with combination chemotherapy. Parassitologia 1999; 41(1-3): 301-8.
58. Fisher LB. Determination of the normal rate and duration of mitosis in human epidermis. Br J Dermatol 1968; 80(1): 24-8.
59. Ferrer P, Tripathi AK, Clark MA, et al. Antimalarial Iron Chelator, FBS0701, Shows Asexual and Gametocyte Plasmodium falciparum Activity and Single Oral Dose Cure in a Murine Malaria Model. PLoS One 2012; 7(5): e37171.
60. Scholl PF, Tripathi AK, Sullivan DJ. Bioavailable iron and heme metabolism in Plasmodium falciparum. Curr Top Microbiol Immunol 2005; 295293-324.
61. Rasoloson D, Shi L, Chong CR, Kafsack BF, Sullivan DJ. Copper pathways in Plasmodium falciparum infected erythrocytes indicate an efflux role for the copper P-ATPase. Biochem J 2004; 381(Pt 3): 803-11.
62. Bleackley MR, Macgillivray RT. Transition metal homeostasis: from yeast to human disease. Biometals 2011; 24(5): 785-809.
63. Myint HY, Berman J, Walker L, et al. Review: Improving the therapeutic index of 8-aminoquinolines by the use of drug combinations: review of the literature and proposal for future investigations. Am J Trop Med Hyg 2011; 85(6): 1010-4.
64. Ganesan S, Tekwani BL, Sahu R, Tripathi LM, Walker LA. Cytochrome P(450)-dependent toxic effects of primaquine on human erythrocytes. Toxicol Appl Pharmacol 2009; 241(1): 14-22.
65. Ganesan S, Chaurasiya ND, Sahu R, Walker LA, Tekwani BL. Understanding the mechanisms for metabolism-linked hemolytic toxicity of primaquine against glucose 6-phosphate dehydrogenase deficient human erythrocytes: evaluation of eryptotic pathway. Toxicology 2012; 294(1): 54-60.
66. Abbasi R, Efferth T, Kuhmann C, et al. The endoperoxide ascaridol shows strong differential cytotoxicity in nucleotide excision repairdeficient cells. Toxicol Appl Pharmacol 2012; 259(3): 302-10.
67. Johnson MA, Croteau R. Biosynthesis of ascaridole: iodide peroxidase-catalyzed synthesis of a monoterpene endoperoxide in soluble extracts of Chenopodium ambrosioides fruit. Arch Biochem Biophys 1984; 235(1): 254-66.
68. O'Neill PM, Miller A, Bishop LP, et al. Synthesis, antimalarial activity, biomimetic iron(II) chemistry, and in vivo metabolism of novel, potent C-10-phenoxy derivatives of dihydroartemisinin. J Med Chem 2001; 44(1): 58-68.
69. O'Neill PM, Posner GH. A medicinal chemistry perspective on artemisinin and related endoperoxides. J Med Chem 2004; 47(12): 2945-64.
70. ter Kuile F, White NJ, Holloway P, Pasvol G, Krishna S. Plasmodium falciparum: in vitro studies of the pharmacodynamic properties of drugs used for the treatment of severe malaria. Exp Parasitol 1993; 76(1): 85-95.
71. Ponmee N, Chuchue T, Wilairat P, Yuthavong Y, Kamchonwongpaisan S. Artemisinin effectiveness in erythrocytes is reduced by heme and heme-containing proteins. Biochem Pharmacol 2007; 74(1): 153-60.
72. Vattanaviboon P, Siritanaratkul N, Ketpirune J, Wilairat P, Yuthavong Y. Membrane heme as a host factor in reducing effectiveness of dihydroartemisinin. Biochem Pharmacol 2002; 64(1): 91-8.
73. Haynes RK, Monti D, Taramelli D, et al. Artemisinin antimalarials do not inhibit hemozoin formation. Antimicrob Agents Chemother 2003; 47(3): 1175.
74. Tripathi AK, Gupta A, Garg SK, Tekwani BL. In vitro betahematin formation assays with plasma of mice infected with Plasmodium yoelii and other parasite preparations: comparative inhibition with quinoline and endoperoxide antimalarials. Life Sci 2001; 69(23): 2725-33.
75. Pandey AV, Tekwani BL, Singh RL, Chauhan VS. Artemisinin, an endoperoxide antimalarial, disrupts the hemoglobin catabolism and heme detoxification systems in malarial parasite. J Biol Chem 1999; 274(27): 19383-8.
76. Cheeseman IH, Miller BA, Nair S, et al. A major genome region underlying artemisinin resistance in malaria. Science 2012; 336(6077): 79-82.
77. Mayxay M, Khanthavong M, Chanthongthip O, et al. No evidence for spread of Plasmodium falciparum artemisinin resistance to Savannakhet Province, Southern Laos. Am J Trop Med Hyg 2012; 86(3): 403-8.
78. Slater AF, Cerami A. Inhibition by chloroquine of a novel haem polymerase enzyme activity in malaria trophozoites. Nature 1992; 355(6356): 167-9.
79. Gilles H, Warrell D. Bruce-Chwatt's Essential malariology. London: Arnold; 1993.
80. Upadhayaya RS, Vandavasi JK, Kardile RA, et al. Novel quinoline and naphthalene derivatives as potent antimycobacterial agents. Eur J Med Chem 2010; 45(5): 1854-67.
81. Moenster RP, Jett RA. Mirtazapine and mefloquine therapy for progressive multifocal leukoencephalopathy in a patient infected with human immunodeficiency virus. Am J Health Syst Pharm 2012; 69(6): 496-8.
82. Gofton TE, Al-Khotani A, O'Farrell B, Ang LC, McLachlan RS. Mefloquine in the treatment of progressive multifocal leukoencephalopathy. J Neurol Neurosurg Psychiatry 2011; 82(4): 452-5.
83. Brickelmaier M, Lugovskoy A, Kartikeyan R, et al. Identification and characterization of mefloquine efficacy against JC virus in vitro. Antimicrob Agents Chemother 2009; 53(5): 1840-9.
84. Worthen DB. The national quinine pool: when quinine went to war. Pharm Hist 1996; 38(3): 143-7.
85. El-Tawil S, Al Musa T, Valli H, et al. Quinine for muscle cramps. Cochrane Database Syst Rev 2010; (12): CD005044.
86. Man-Son-Hing M, Wells G. Meta-analysis of efficacy of quinine for treatment of nocturnal leg cramps in elderly people. BMJ 1995; 310(6971): 13-7.
87. Baliga RS, Wingo CS. Quinine induced HUS-TTP: an unusual presentation. Am J Med Sci 2003; 326(6): 378-80.
88. Park YA, Hay SN, King KE, et al. Is it quinine TTP/HUS or quinine TMA? ADAMTS13 levels and implications for therapy. J Clin Apher 2009; 24(3): 115-9.
89. Slater AF. Chloroquine: mechanism of drug action and resistance in Plasmodium falciparum. Pharmacol Ther 1993; 57(2-3): 203-35.
90. O'Neill PM, Bray PG, Hawley SR, Ward SA, Park BK. 4-Aminoquinolines--past, present, and future: a chemical perspective. Pharmacol Ther 1998; 77(1): 29-58.
91. O'Neill PM, Ward SA, Berry NG, et al. A medicinal chemistry perspective on 4-aminoquinoline antimalarial drugs. Curr Top Med Chem 2006; 6(5): 479-507.
92. Pisciotta JM, Coppens I, Tripathi AK, et al. The role of neutral lipid nanospheres in Plasmodium falciparum haem crystallization. Biochem J 2007; 402(1): 197-204.
93. Sullivan DJ. Theories on malarial pigment formation and quinoline action. Int J Parasitol 2002; 32(13): 1645-53.
94. Solomonov I, Osipova M, Feldman Y, et al. Crystal nucleation, growth, and morphology of the synthetic malaria pigment betahematin and the effect thereon by quinoline additives: the malaria pigment as a target of various antimalarial drugs. J Am Chem Soc 2007; 129(9): 2615-27.
95. Cabantchik ZI, Moody-Haupt S, Gordeuk VR. Iron chelators as anti-infectives; malaria as a paradigm. FEMS Immunol Med Microbiol 1999; 26(3-4): 289-98.
96. Harvey PW, Bell RG, Nesheim MC. Iron deficiency protects inbred mice against infection with Plasmodium chabaudi. Infect Immun 1985; 50(3): 932-4.
97. Raventos-Suarez C, Pollack S, Nagel RL. Plasmodium falciparum: inhibition of in vitro growth by desferrioxamine. Am J Trop Med Hyg 1982; 31(5): 919-22.
98. Atkinson CT, Bayne MT, Gordeuk VR, Brittenham GM, Aikawa M. Stage-specific ultrastructural effects of desferrioxamine on Plasmodium falciparum in vitro. Am J Trop Med Hyg 1991; 45(5): 593-601.
99. Loyevsky M, Sacci JB, Jr., Boehme P, et al. Plasmodium falciparum and Plasmodium yoelii: effect of the iron chelation prodrug dexrazoxane on in vitro cultures. Exp Parasitol 1999; 91(2): 105-14.
100. Mabeza GF, Loyevsky M, Gordeuk VR, Weiss G. Iron chelation therapy for malaria: a review. Pharmacol Ther 1999; 81(1): 53-75.
101. Krungkrai J, Burat D, Kudan S, Krungkrai S, Prapunwattana P. Mitochondrial oxygen consumption in asexual and sexual blood stages of the human malarial parasite, Plasmodium falciparum. Southeast Asian J Trop Med Public Health 1999; 30(4): 636-42.
102. Krungkrai J, Prapunwattana P, Krungkrai SR. Ultrastructure and function of mitochondria in gametocytic stage of Plasmodium falciparum. Parasite 2000; 7(1): 19-26.
103. Vaidya AB, Mather MW. Mitochondrial evolution and functions in malaria parasites. Annu Rev Microbiol 2009; 63249-67.
104. Learngaramkul P, Petmitr S, Krungkrai SR, Prapunwattana P, Krungkrai J. Molecular characterization of mitochondria in asexual and sexual blood stages of Plasmodium falciparum. Mol Cell Biol Res Commun 1999; 2(1): 15-20.
105. Young JA, Fivelman QL, Blair PL, et al. The Plasmodium falciparum sexual development transcriptome: a microarray analysis using ontology-based pattern identification. Mol Biochem Parasitol 2005; 143(1): 67-79.
106. Thuma PE, Mabeza GF, Biemba G, et al. Effect of iron chelation therapy on mortality in Zambian children with cerebral malaria. Trans R Soc Trop Med Hyg 1998; 92(2): 214-8.
107. Neufeld EJ. Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions. Blood 2006; 107(9): 3436-41.
108. Ding WQ, Lind SE. Metal ionophores-an emerging class of anticancer drugs. IUBMB Life 2009; 61(11): 1013-8.
109. Baer K, Klotz C, Kappe SH, Schnieder T, Frevert U. Release of hepatic Plasmodium yoelii merozoites into the pulmonary microvasculature. PLoS Pathog 2007; 3(11): e171.
110. Chilengi R, Juma R, Abdallah AM, et al. A phase I trial to evaluate the safety and pharmacokinetics of low-dose methotrexate as an anti-malarial drug in Kenyan adult healthy volunteers. Malar J 2011; 1063.
111. Reynolds JM, El Bissati K, Brandenburg J, Gunzl A, Mamoun CB. Antimalarial activity of the anticancer and proteasome inhibitor bortezomib and its analog ZL3B. BMC Clin Pharmacol 2007; 713.
112. Bell A. Antimalarial peptides: the long and the short of it. Curr Pharm Des 2011; 17(25): 2719-31.
113. Yount NY, Yeaman MR. Emerging themes and therapeutic prospects for anti-infective peptides. Annu Rev Pharmacol Toxicol 2012; 52337-60.
114. Wells TN, Poll EM. When is enough enough? The need for a robust pipeline of high-quality antimalarials. Discov Med 2010; 9(48): 389-98.